Stock IMNM IMMUNOME, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Immunome, Inc.

Equities

IMNM

US45257U1088

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
14.94 USD +1.36% Intraday chart for Immunome, Inc. +5.06% +39.63%
May. 31 Piper Sandler Initiates Immunome With Overweight Rating, $27 Price Target MT
May. 21 Immunome Insider Bought Shares Worth $1,388,072, According to a Recent SEC Filing MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Immunome Promotes Max Rosett to Chief Financial Officer
AQ
Immunome Announces Completion of Purchase of Assets from Atreca
BU
Immunome Announces Promotion of Max Rosett to Chief Financial Officer
BU
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
BU
Immunome to Present at 2024 Bank of America Healthcare Conference
BU
Immunome Appoints Kinney Horn as Chief Business Officer
BU
Immunome Appoints Sandra M. Swain to Board of Directors
BU
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research Annual Meeting
AQ
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
BU
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
BU
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
BU
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
AQ
Immunome to Participate in the Leerink Partners Global Biopharma Conference
BU
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
AQ
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
BU
Immunome Recognizes Ayala Pharmaceuticals Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
AQ
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
BU
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
AQ
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
BU
Immunome Announces Pricing of Public Offering of Common Stock
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMNM Stock
  4. News Immunome, Inc.
  5. Press Releases